IOL Chemicals & Pharmaceuticals announced that the company`s product �Metformin Hydrochloride� has been approved by Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA), China.This will enable the Company to export Metformin Hydrochloride in China Market. Metformin Hydrochloride is an antidiabetic drug which is used to manage the high blood sugar levels in diabetes patients. Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 6 February 2024, inter alia, have recommended the interim dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 February 2024.Powered by Capital Market - Live News

Net profit of IOL Chemicals & Pharmaceuticals rose 138.03% to Rs 37.87 crore in the quarter ended September 2023 as against Rs 15.91 crore during the previous quarter ended September 2022. Sales rose 0.72% to Rs 545.30 crore in the quarter ended September 2023 as against Rs 541.41 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales545.30541.41 1 OPM %11.775.89 - PBDT66.8733.46 100 PBT51.1822.14 131 NP37.8715.91 138 Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 November 2023.Powered by Capital Market - Live News